Volume 30, No 3, Mar 2020

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 30 Issue 3, March 2020: 269-271   |  Open Access

LETTERS TO THE EDITOR

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Manli Wang¹, Ruiyuan Cao², Leike Zhang¹, Xinglou Yang¹, Jia Liu¹,Mingyue Xu¹, Zhengli Shi¹, Zhihong Hu ¹, Wu Zhong² and Gengfu Xiao ¹

¹State Key Laboratory of Virology, Wuhan Institute of Virology,Center for Biosafety Mega-Science, Chinese Academy of Sciences,430071 Wuhan, China and ²National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, 100850 Beijing, China
These authors contributed equally: Manli Wang, Ruiyuan Cao, Leike Zhang, Xinglou Yang.
Correspondence: Zhihong Hu (huzh@wh.iov.cn) orWu Zhong (zhongwu@bmi.ac.cn) or Gengfu Xiao (xiaogf@wh.iov.cn)

In December 2019, a novel pneumonia caused by a previously unknown pathogen emerged in Wuhan, a city of 11 million people in central China. The initial cases were linked to exposures in a seafood market in Wuhan.1 As of January 27, 2020, the Chinese authorities reported 2835 confirmed cases in mainland China, including 81 deaths. Additionally, 19 confirmed cases were identified in Hong Kong, Macao and Taiwan, and 39 imported cases were identified in Thailand, Japan, South Korea, United States, Vietnam, Singapore, Nepal, France, Australia and Canada. The pathogen was soon identified as a novel coronavirus (2019-nCoV), which is closely related to sever acute respiratory syndrome CoV (SARS-CoV).2 Currently, there is no specific treatment against the new virus. Therefore, identifying effective antiviral agents to combat the disease is urgently needed.

https://doi.org/10.1038/s41422-020-0282-0

FULL TEXT | PDF

Browse 935